May 2008 Issue of MMM
One of the fundamental challenges facing pharmaceutical companies is finding a balance between developing and manufacturing lifesaving medications and making money for shareholders.
With the deadline for submitting entries for the 2008 MM&M Awards only a few weeks away, James Chase unveils this year's lineup of judges who ...
While the overall US pharmaceuticals market grew modestly in 2007, product exclusivity and safety issues continued to weigh heavily on the industry. MM&M charts the ...
The pioneers of biotech began their journey with an endless level of optimism and promise. So, why has the goal of redefining the landscape and ...
It's Asthma and Allergy Awareness Month and the seasonal allergies category is as congested as ever. But a slew of patent expirations poses a greater ...
Slight gains in ad spending were reported among only three of the eight specialty markets with laboratory journals leading the pack. PERQ/HCI's Eugene M. May ...
Joe Jimenez isn't interested in lamenting the state of the industry. He's focused on one thing: adapting Novartis to thrive in a mercurial environment.
I recently attended the PMRG conference in Phoenix, and came away with several realizations.
Even if I had another topic planned, how could I not write this month about Zetia?
On Jan. 14, Schering-Plough released preliminary results of its ENHANCE clinical trial, finding that Vytorin (Zocor/Zetia) did nothing more than generic Zocor alone to slow ...
Med Ed Report
A bill introduced in the House of Representatives in March would mandate the reporting of all gifts to physicians worth more than $25—including education—and violators ...
Two foes of commercially supported CME, the American Medical Student Association and PharmedOut.org, are partnering to present How to Hold Pharma-Free Meetings, a guide for ...
The National Commission for Certification of CME Professionals (or NC-CME) is beta-testing its new exam later this month in San Francisco, before the CBI Biopharmaceutical ...
Gullapalli and Associates named David Clausen SVP, educational strategy.
A study by Best Practices LLC touts "significant opportunity for maximizing resources through centralization and innovative use of e-CME."
The Canadian Medical Association Journal ran an editorial excoriating industry-funded education, which editor-in-chief Dr. Paul Hébert said "embellishes the positive elements of studies and downplays ...
The Association of Medical Media (AMM) has announced the winners of the 2008 Nexus Awards.
A report released by Best Practices indicates that leading pharma and biopharmaceutical companies are rethinking their publication strategies, in light of new transparency guidelines.
Quadrant HealthCom named Charles Nemeroff, MD, PhD, editor-in-chief of NeuroPsychiatry Reviews.
Pfizer's request for confidential documents from The New England Journal of Medicine was rejected by a federal judge in Boston.
SAGE will launch Sports Health, a bi-monthly publication, in January 2009.
The Nielsen Company will acquire IAG Research, Inc. for a purchase price of $225 million, according to a company release.
PERQ/HCI data suggest that the slowdown in journal ad sales is hitting both medical-surgical journals and specialty titles as the professional ad spend fell again ...
When you search for information on the Internet, do you bookmark the sites that deliver the results you are seeking?
Doctors rate Merck's ePromotion efforts as tops in the industry, according to pharma marketing data firm Verispan.
Search engines continue to be a primary way for US consumers to arrive at healthcare Websites, according to online intelligence firm Hitwise.
Healthcare customer relationship management (CRM) firm Cegedim Dendrite has inked a deal with Microsoft in an effort to boost the effectiveness of its software offerings ...
In an Associated Press tally, seven out of the 12 companies surveyed reported reductions in work force by 10% or more since January 2007.
Winning a place on formularies in the hospital marketplace may not require face time with a physician, research from Best Practices reveals.
Direct Response Media, a direct response TV management company, has named David DiMatteo group account director.
The Amacore Group, a health and medical insurance company, has acquired US Health Benefits Group, Inc.
Cossette New York has hired Anupama Bhoopathy as account supervisor.
A Medical Care study found that drug sampling does lead to greater consumer spending on drugs.
Congress is gearing up yet another investigation of consumer drug advertising.
Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients ...
The European Federation of Pharmaceutical Industries and Associations said it doesn't want "push" TV, radio and print mass media for Rx drug info.
A New England Journal of Medicine study found Zetia uptake rose much more quickly after introduction in the US than in Canada, and suggested DTC ...
PhRMA president Billy Tauzin told The Pink Sheet that DTC ads have been resented because "in many cases, we were talking about new products that ...
DTC spend is slowing, and consumer drug marketers project a shift in spending toward events, rebates/coupons and product placement this year, according to a survey ...
The conventional wisdom is that uncertainty about the 2008 elections makes healthcare strategic planning difficult. Or, maybe not.
WeissComm Partners has promoted Diane Weiser to the position of president and chief operating officer.
Voluminous press coverage over cholesterol drug safety have led to a study measuring consumer perception.
Eisai unveiled its 2008 Senior Health Digest at the Academy of Managed Care Pharmacy's 20th Annual Meeting & Showcase, in April.
TNS Healthcare has unveiled a call assessment tool measuring detail effectiveness across countries, brands and categories.
The lower the FDA sinks in public esteem, the more it shows a bunker mentality, withdrawing into its shell and stalling on media inquiries.
FDA pre-emption of "failure-to-warn" state lawsuits over drug risks does nothing to benefit the agency or the public and can prevent information that is helpful ...
The FDA's director of new drugs, John Jenkins, has told his reviewers that they may miss Prescription Drug User Fee Act (PDUFA) deadlines by up ...
Sen. Charles Grassley (R-IA) says he is concerned that the FDA's Safety First initiative is merely cosmetic and will not make fundamental changes he says ...
Sen. Edward Kennedy (D-MA) says the FDA should build databases to enable it to determine where drug companies obtain their ingredients and what they are ...
Philadelphia Common Pleas judge Mark Bernstein has ruled that branded drug companies may be liable for money spent on the generic version of their drugs ...
As DTC promoters push all kinds of genetic tests, a high-level HHS advisory committee is preparing to recommend that FDA should have some level of ...
Rep. Anna Eshoo (D-CA) and Rep. Joe Barton (R-TX) have introduced legislation that would create a regulatory pathway for the FDA to approve follow-on or ...
The pharmaceutical industry's character—its products, messages, promo channels and even its audiences—have been determined by governmental regulation and trade conventions practiced by media and manufacturers.
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- As immuno-oncology therapies evolve, so will the marketing
- GSK Consumer Healthcare to prioritize digital after agency review
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Tuesday, July 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- 8 ways for pharma to improve the way it uses Twitter
- Five things for pharma marketers to know: Thursday, July 28, 2016
- Infographic: Type 2 diabetes, a country-by-country snapshot
- Moving Forward — Without the Promotion
- Sponsored Podcast: No Patient Left Behind: Connecting Rare Disease Patients to Orphan Drug Manufacturers